FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Biocure Technology Inc. (the "Issuer").

Trading Symbol: CURE

Number of Outstanding Listed Securities:98,127,908

Date: February 4, 2021

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   BiocurePharm Korea (BPK), a subsidiary of Biocure Technology Inc., has entered into a memorandum of understanding (MOU) with Symbasis GmbH. The parties have expressed a common interest in developing a CAR-T therapy for chronic lymphocyte leukemia (CLL) and wish to sign this MOU for the purpose of confirming their intention in respect to the development.

   The purpose of this MOU is to establish a joint venture in Germany under the name Oncocart for clinical trials, production and marketing in Europe (potentially including other regions of the world) of ROR1-based products for the CAR-T therapy, the target indication of which is CLL. The MOU is intended to form the basis of discussions and negotiations between the parties for the purpose of entering into final agreements without creating any obligation to do so. Both parties agree that this joint venture will enable them to bring together an extremely experienced group of experts and professionals, allowing for all phases of the development to advance more effectively.

2. Provide a general overview and discussion of the activities of management

   BiocurePharm Korea (BPK), a subsidiary of Biocure Technology Inc., has entered into a memorandum of understanding (MOU) with Symbasis GmbH. The parties have expressed a common interest in developing a CAR-T therapy for chronic lymphocyte leukemia (CLL) and wish to sign this MOU for the purpose of confirming their intention in respect to the development.

   The purpose of this MOU is to establish a joint venture in Germany under the name Oncocart for clinical trials, production and marketing in Europe (potentially including other regions of the world) of ROR1-based products for the CAR-T therapy, the target indication of which is CLL. The MOU is intended to form the basis of discussions and negotiations between the parties for the purpose of entering into final agreements without creating any obligation to do so. Both parties agree that this joint venture will enable them to bring together an extremely experienced group of experts and professionals, allowing for all phases of the development to advance more effectively.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

   Not applicable to the issuer during the month of January 2021

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable to the issuer during the month of January 2021

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable to the issuer during the month of January 2021

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship..

Not applicable to the issuer during the month of January 2021

8. Describe the acquisition of new customers or loss of customers.

Not applicable to the issuer during the month of January 2021

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable to the issuer during the month of January 2021

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable to the issuer during the month of January 2021

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable to the issuer during the month of January 2021

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable to the issuer during the month of January 2021

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Other than in relation to accounts payable incurred by the Issuer in the ordinary course of business with its service providers, not applicable to the issuer during the month of January 2021.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds[(1)]

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

Not applicable to the issuer during the month of January 2021

16. Provide details of any changes in directors, officers or committee members.

Not applicable to the issuer during the month of January 2021

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Not applicable to the issuer during the month of January 2021

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated February 4th, 2021.

Konstantin Lichtenwald
Name of Director or Senior Officer

"Konstantin Lichtenwald"
Signature
CFO and Director
Official Capacity

Issuer Details Name of Issuer BIOCURE TECHNOLOGY INC	For Month End January 2021	Date of Report YY/MM/DD 21/02/04
Issuer Address 300-1055 West Hastings Street		
City/Province/Postal Code Vancouver BC, V6E 2E9	Issuer Fax No. (604) 685 5120	Issuer Telephone No. (604) 609 7146
Contact Name Konstantin Lichtenwald	Contact Position Director	Contact Telephone No. (604) 609 7146
Contact Email Address klichtenwald@bicuretech.com	Web Site Address www.biocuretech.com	